Overview

A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception.

Phase:

PHASE2

Details

Lead Sponsor:

Premier Research

Collaborator:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Treatments:

levonorgestrel butanoate